AstraZeneca PLC

Pharmaceuticals and BiotechnologyFounded 1999

Market Data Current As Of: September 12, 2026

Related Competitor Intelligence

Compare market positioning with top industry peers

Competitor

Explore AstraZeneca

Core profile pages, annual revenue records, and related research hubs for this company.

AstraZeneca PLC

Pharmaceuticals and BiotechnologyFounded 1999

Reviewed by Swet Parvadiya

Last reviewed: September 12, 2026

Market Data Current As Of: September 12, 2026

Financial Performance

AstraZeneca Revenue & Financials

Name: AstraZeneca PLC Annual Revenue History
Creator: CorpDigest
License: https://corpdigest.com/terms

Revenue

$58.7B

Market Cap

$210.4B

Net Income

$10.2B

Employees

89,900

Financial Analysis

AstraZeneca operates as one of the most successful oncology pipelines in the global pharmaceutical industry. Under the long-tenured leadership of CEO Pascal Soriot, the British-Swedish multinational generated exactly $45.8 billion in revenue and maintains a $210.4 billion market cap with exactly 89900 employees. Having fully moved past the zero-margin distribution of its COVID-19 vaccine, AstraZeneca's financial narrative in 2026 is entirely driven by its blockbuster cancer drugs (specifically Tagrisso, Enhertu, and Imfinzi). the company has integrated its $39 billion acquisition of Alexion Pharmaceuticals, giving it a dominant, high-margin foothold in the rare disease space.

Revenue Trend Analysis

YoY Change

+8.6%

2-Year CAGR

+13.2%

Peak Year

2025

Trend

Consistent Growth

AstraZeneca PLC has reported revenue across 3 fiscal years, compounding at +13.2% annually over 2 years. The most recent year saw a 8.6% increase versus the prior year. Revenue peaked in 2025 at $58.7B. Out of 2 reported periods, 2 showed growth and 0 showed a decline.

Annual Revenue History

Fiscal Year	Revenue	Net Income	YoY Change
FY2025	$58.7B	$10.2B	+8.6%
FY2024	$54.1B	—	+18.0%
FY2023	$45.8B	—	—

Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.

Click any row to see year details.

Related Companies

Eli Lilly and Company Novartis AG Novo Nordisk A/S Bausch Health Companies Inc.

Compare AstraZeneca PLC Revenue With Competitors

AstraZeneca PLC vs Eli Lilly and Company →AstraZeneca PLC vs Novartis AG →AstraZeneca PLC vs Novo Nordisk A/S →AstraZeneca PLC vs Bausch Health Companies Inc. →

AstraZeneca Revenue and Financial FAQ

What was AstraZeneca PLC's reported annual revenue for FY2025?

AstraZeneca PLC reported approximately $45.8B in fiscal year 2025 with a team of 89,900 employees worldwide.

How does AstraZeneca PLC allocate capital and manage operating margins?

AstraZeneca PLC strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.

What is the long-term financial outlook for AstraZeneca PLC in Pharmaceuticals and Biotechnology?

Financial performance in Pharmaceuticals and Biotechnology is driven by steady cash generation and pricing power, enabling AstraZeneca PLC to reinvest in high-return strategic initiatives.

Cite or embed this data

Using these figures? Please credit CorpDigest with a link.

Cite this page

CorpDigest. "AstraZeneca PLC Revenue & Financials." CorpDigest, https://corpdigest.com/company/astrazeneca/financials.

Embed this data

<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>AstraZeneca PLC reported $59B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/astrazeneca/financials" target="_blank" rel="noopener">CorpDigest — AstraZeneca PLC financials</a></div>

Related Competitor Intelligence

Compare market positioning with top industry peers

Competitor

Eli Lilly and Company

View Competitor Intelligence

Competitor

Novartis AG

View Competitor Intelligence

Competitor

Novo Nordisk A/S

View Competitor Intelligence

Competitor

Bausch Health Companies Inc.

View Competitor Intelligence

Competitor

Pfizer

View Competitor Intelligence

Competitor

Roche

View Competitor Intelligence

Explore AstraZeneca

Core profile pages, annual revenue records, and related research hubs for this company.

Financial Analysis

Fiscal Year

Revenue

Net Income

YoY Change

FY2025

$58.7B

$10.2B

+8.6%

FY2024

$54.1B

—

+18.0%

FY2023

$45.8B

—

AstraZeneca Revenue and Financial FAQ

What was AstraZeneca PLC's reported annual revenue for FY2025?

AstraZeneca PLC reported approximately $45.8B in fiscal year 2025 with a team of 89,900 employees worldwide.

How does AstraZeneca PLC allocate capital and manage operating margins?

AstraZeneca PLC strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.

What is the long-term financial outlook for AstraZeneca PLC in Pharmaceuticals and Biotechnology?

Financial performance in Pharmaceuticals and Biotechnology is driven by steady cash generation and pricing power, enabling AstraZeneca PLC to reinvest in high-return strategic initiatives.

Cite or embed this data

Using these figures? Please credit CorpDigest with a link.

Cite this page

CorpDigest. "AstraZeneca PLC Revenue & Financials." CorpDigest, https://corpdigest.com/company/astrazeneca/financials.

Embed this data

<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>AstraZeneca PLC reported $59B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/astrazeneca/financials" target="_blank" rel="noopener">CorpDigest — AstraZeneca PLC financials</a></div>